EN
ENSC.US Ensysce Biosciences Inc
- Market cap
- USD 8.14M
- P/E
- -
- P/B
- 0.86x
- ROE
- -428.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ENSC.US undervalued?
Graham numberThe Graham number of Ensysce Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ensysce Biosciences Inc fundamental analysis
No fundamental analysis for Ensysce Biosciences Inc yet.
Ensysce Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead…
Full company profileEnsysce Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ensysce Biosciences Inc annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 1.76M | 3.93M | 3.53M | 2.52M | 2.23M | 5.21M | 5.07M | 5.74M |
| Gross Profit | - | -1.56M | -3.33M | 3.93M | 3.53M | -17.3M | -5.36M | -2.01M | -5.31M | -107M |
| Operating Income | -147K | -959K | -3.33M | -1.61M | -19.9M | -24.2M | -10.7M | -6.73M | -10.2M | -118M |
| EBITDA | -27.6K | -959K | -3.33M | -1.61M | -19.9M | -24.2M | -10.3M | -6.70M | -10.2M | -118M |
| Net Income | -31.2K | 2.12M | 1.48M | 56.8K | -29.1M | -25.0M | -10.6M | -7.99M | -10.2M | -118M |
| EPS | -0.01 | 0.35 | 15 | 0.83 | -347 | -139 | -4.69 | -4.57 | -0.40 | -6.47 |
| Balance Sheet | ||||||||||
| Total Assets | 202M | 205M | 197M | 352K | 16.4M | 5.89M | 2.71M | 5.60M | 7.45M | 31.0M |
| Total Liabilities | 7.16M | 7.44M | 10.3M | 7.01M | 24.6M | 9.91M | 3.36M | 2.22M | 4.57M | 3.84M |
| Shareholders' Equity | 195M | 197M | 186M | -6.66M | -8.16M | -4.03M | -323K | 3.71M | 3.21M | 27.4M |
| Cash & Short-term Investments | 2.09M | 1.66M | 1.06M | 194K | 12.3M | 3.15M | 1.12M | 3.50M | 4.31M | 29.7M |
| Total Debt | - | - | 3.19M | 5.06M | 17.2M | 4.41M | 855K | 302K | 307K | 155K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -252K | -1.24M | 11.0M | -1.25M | -8.24M | -17.9M | -10.8M | -7.50M | -7.81M | -9.15M |
| Capital Expenditure | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 | 0.00 | 2.00 | 0.00 | 124K | 69.0K |
| Free Cash Flow | -252K | -1.24M | 11.0M | -1.25M | -8.24M | -17.9M | -10.8M | -7.50M | -7.93M | -9.22M |
| Ratios | ||||||||||
| ROE | 0.0% | 1.1% | 0.8% | - | - | - | - | -215.4% | -316.6% | -428.8% |
| ROA | 0.0% | 1.0% | 0.8% | 16.1% | -177.5% | -424.2% | -391.9% | -142.7% | -136.5% | -380.1% |
| Net Profit Margin | - | - | 83.7% | 1.4% | -825.4% | -989.2% | -475.7% | -153.3% | -200.8% | -2,048.8% |
| Debt to Equity | - | - | 0.02x | - | - | - | - | 0.08x | 0.10x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ensysce Biosciences Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 290M | 166 | - |
| 2023 | USD 12.9K | 0.01 | - |
| 2022 | USD 913K | 5.08 | - |
| 2021 | USD 803B | 9,559,142 | - |
| 2020 | - | - | - |
| 2019 | USD 500K | 5.09 | 33.9% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:15 on Dec 6, 2024.
Who owns Ensysce Biosciences Inc
- Insiders 4.72%
- Institutions 6.83%
- Public & others 88.45%
- Shares outstanding 19.5M
- Free float 18.5M
Top funds holding ENSC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 60.7K | 0.31% | 0.00% | Sep 2026 |
Top institutions holding ENSC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jane Street Group LLC | 209K | 1.07% | +1,438.93% | Jun 2026 |
| Adage Capital Partners Gp LLC | 150K | 0.77% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 95.4K | 0.49% | +616.53% | Jun 2026 |
| Perceptive Advisors LLC | 86.7K | 0.45% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 86.2K | 0.44% | +50.26% | Jun 2026 |
| XTX Topco Ltd | 77.0K | 0.40% | +216.07% | Jun 2026 |
| Geode Capital Management, LLC | 62.2K | 0.32% | -15.83% | Jun 2026 |
| HRT FINANCIAL LLC | 54.4K | 0.28% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 34.3K | 0.18% | 0.00% | Jun 2026 |
| TRU INDEPENDENCE ASSET MANAGEMENT 2, LLC | 13.0K | 0.07% | 0.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 13.0K | 0.07% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 12.9K | 0.07% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 6.09K | 0.03% | 0.00% | Jun 2026 |
| Barclays PLC | 1.44K | 0.01% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 641.00 | 0.00% | +31.89% | Jun 2026 |
| BlackRock Inc | 65.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
| FNY Investment Advisers, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
Ensysce Biosciences Inc company profile
- Company name
- Ensysce Biosciences Inc
- Ticker
- ENSC.US
- Exchange
- USA Stocks
- Listed since
- Feb 26, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- 7946 Ivanhoe Avenue, La Jolla, CA, United States, 92037
- Phone
- 858 263 4196
- Website
- ensysce.com
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Ensysce Biosciences Inc management
4- Dr. D. Lynn Kirkpatrick Ph.D.CEO & Director · born 1957
- Dr. William K. Schmidt Ph.D.Chairman of Clinical Advisory Board & Chief Medical Officer · born 1951
- Dr. Linda Pestano Ph.D.Chief Development Officer · born 1969
- Mr. Richard LangfordChief Medical Officer of Cy Biopharma